Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis

Additional Information

Published Date Mar 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4130
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis.

    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
A&G Pharmaceutical
AB Science
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Biokine Therapeutics
BioLineRx
Bionovo
BioNumerik
BioSante
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chong Kun Dang
Choongwae
Circadian Technologies
Clavis Pharma
CLL Pharma
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CritiTech
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
Dong-A
Dyax
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
FibroGen
Five Prime Therapeutics
Fresenius
Galapagos
Galectin Therapeutics
GammaCan
Gemin X Biotechnologies
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Hanmi
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
Karus Therapeutics
Kiadis
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Morvus Technology
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Valeant
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zeria
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
A6
ABT-510
AEG-35156
afatinib
aflibercept
AGS-1C4D4
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
apricoxib
ARC-100
ARQ-197
astuprotimut-r
atrasentan
axitinib
bardoxolone methyl
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
BMS-690514
bosutinib
brivanib alaninate
brivudine
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
crizotinib
CRLX-101
dacomitinib
dalotuzumab
dasatinib
DI-17E6
docetaxel
dovitinib lactate
doxorubicin
E-7820
emepepimut-S
endostatin
eniluracil
ENMD-2076
enzastaurin hydrochloride
erlotinib
etoposide (1)
etoposide phosphate
everolimus
Exherin
foretinib
fosbretabulin tromethamine
ganitumab
gefitinib
GliaAtak
GSK-1120212
GT-111
GV-1001
GVAX
HBP-347
icotinib hydrochloride
icrucumab
imatinib mesilate
IMP-321
iniparib
interferon (gamma1b)
intetumumab
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
JI-101
KD032
L19-IL2
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
LipoVIL12
LY-2275796
masitinib
MetXia
MGCD-265
midostaurin
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
nadroparin
necitumumab
NGR-TNF
nimotuzumab
oblimersen sodium
olaparib
ON-01910
OTS-102
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
PF-4856884
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-12
RAF-265
ramucirumab
regorafenib
Rexin-G
ridaforolimus
romidepsin
RX-0201
selumetinib
siltuximab
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
topotecan
trabedersen
trastuzumab
TRC-105
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vismodegib
volociximab
WX-671
XL-184
XL-647
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis.
    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Prostate Cancer. Learn More


Triple Analysis: Lymphoma, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More